1832 Asset Management L.P. Buys 353 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

1832 Asset Management L.P. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 18.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,254 shares of the biopharmaceutical company’s stock after acquiring an additional 353 shares during the quarter. 1832 Asset Management L.P.’s holdings in Regeneron Pharmaceuticals were worth $1,980,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Eudaimonia Advisors LLC increased its position in Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares during the period. Drive Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares in the last quarter. MCF Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. LCM Capital Management Inc boosted its stake in Regeneron Pharmaceuticals by 2.5% during the fourth quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 12 shares in the last quarter. Finally, TrinityPoint Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 12 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $1,002.95 on Friday. The stock has a market capitalization of $110.52 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.07 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,016.00. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The business has a 50-day moving average price of $949.32 and a two-hundred day moving average price of $927.90.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on REGN. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Truist Financial restated a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $1,185.00 to $1,200.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $989.86.

Read Our Latest Report on Regeneron Pharmaceuticals

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,397,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,397,202. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. In the last three months, insiders sold 55,612 shares of company stock valued at $54,346,970. 7.48% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.